Vitamin D for adolescent acne: the IGF-1 and sebum trial evidence

Acne vulgaris affects most adolescents to some degree and is one of the most-Googled health complaints in the 13–17 age range. The standard pharmacologic ladder — topical retinoids, benzoyl peroxide, topical antibiotics, oral antibiotics, hormonal therapy in girls, isotretinoin — works well but has tolerability and access barriers. Vitamin D's possible role has attracted attention because of observational data linking low 25-hydroxyvitamin D levels to acne severity and a handful of randomized trials showing modest improvement with repletion.

The observational link

A 2014 case-control study in Korean adolescents found that mean serum 25-hydroxyvitamin D was significantly lower in patients with nodulocystic acne than in age-matched controls (10.0 vs 15.4 ng/mL). Similar correlations have been reported in studies from Turkey, the U.S., and Iran. The association is reproducible but cross-sectional — it cannot tell us whether low vitamin D causes acne, whether acne (or its associated inflammation) causes low vitamin D, or whether both are downstream of a third factor [1].

Plausible mechanisms

Vitamin D receptors are expressed on sebocytes, keratinocytes, and immune cells in the pilosebaceous unit. 1,25-dihydroxyvitamin D modulates the differentiation of sebocytes, reduces sebum lipogenesis in vitro, and downregulates the inflammatory response of keratinocytes to Cutibacterium acnes (formerly Propionibacterium acnes). Vitamin D also reduces IGF-1 signaling, which is a major driver of sebum production and follicular hyperkeratinization in adolescent acne. The mechanistic picture is consistent across multiple in vitro lines of evidence [2,3].

The randomized trials

A 2016 randomized trial in 39 adolescents and young adults with moderate to severe acne and documented vitamin D deficiency tested 1,000 IU/day of vitamin D3 versus placebo for 8 weeks. The supplemented group showed significantly reduced inflammatory lesion counts (mean reduction approximately 35% versus 6% in placebo). Cyst counts and total lesion counts also improved. The trial was small but well-controlled [4]. A 2018 Iranian trial of similar design showed comparable effects.

What the trials do not show

The published trials enrolled patients with low baseline vitamin D status. They did not test supplementation in adolescents who were already replete. They were small (typically 30–80 patients), short (8–16 weeks), and used clinical lesion-count endpoints rather than patient-reported outcomes or disease-specific quality of life. No head-to-head comparisons with standard topical retinoids exist. The current evidence supports vitamin D as a useful adjunct in adolescents with documented deficiency and moderate-severity acne, not as a primary or substitute therapy [5].

How to dose in practice

For adolescents with serum 25-hydroxyvitamin D below 20 ng/mL and active acne, daily supplementation with 1,000–2,000 IU of vitamin D3 for 12 weeks is consistent with the trial protocols. For adolescents with already-replete levels, supplementation is unlikely to improve acne and is not justified for that indication. The skeletal RDA for vitamin D in adolescents (600 IU/day) is a floor, not a ceiling, and 1,000–2,000 IU is well within the safe range. Monitoring 25-hydroxyvitamin D after 3 months of supplementation is appropriate [6].

Where dermatology guidelines stand

The American Academy of Dermatology's acne guidelines do not yet recommend routine vitamin D supplementation as part of acne management because the trial evidence is limited. Several pediatric and dermatologic societies have acknowledged the deficiency association and suggested that checking vitamin D status in adolescents with moderate to severe acne is reasonable, particularly in higher-latitude regions or in adolescents with limited sun exposure [7]. The recommendation is to address deficiency for general health reasons, with acne improvement as a possible bonus rather than a guaranteed outcome.

The bottom line

Vitamin D deficiency is common in adolescents and is more common in those with moderate to severe acne. Small randomized trials suggest that correcting deficiency modestly improves inflammatory acne lesions over 8–12 weeks. This is a reasonable adjunct, not a replacement, for standard acne therapy. Adolescents with persistent or scarring acne should be evaluated by a clinician for guideline-directed care; vitamin D status is one input to consider, not the primary lever. Mega-dosing vitamin D for acne is not supported and is not recommended.